-Reuters
Piper Sandler Maintains Neutral on Blueprint Medicines, Lowers Price Target to $65
Piper Sandler analyst Christopher Raymond maintains Blueprint Medicines (NASDAQ:BPMC) with a Neutral and lowers the price target from $84 to $65.
FOMC: Powell Says We Think Supply And Demand Will Meet In Coming Months
-Reuters
Related Posts
Tilray Joins Two Jefferies Investor Conferences – Healthcare And Consumer
Canadian cannabis giant Tilray, Inc. (NASDAQ: TLRY) (TSX: TLRY) confirmed Thursday it will participate in two Jefferies investor conferences.
Morgan Stanley Maintains Underweight on Avanos Medical, Raises Price Target to $26
Morgan Stanley analyst Drew Ranieri maintains Avanos Medical (NYSE:AVNS) with a Underweight and raises the price target from $24 to $26.
70 Stocks Moving In Monday’s Mid-Day Session
Gainers
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.